about
Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies.FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factorPO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status.Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonatesClotting mechanisms and cancer: implications in thrombus formation and tumor progression.Heparin in tumor progression and metastatic dissemination.Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.Venous thromboembolism in the hematologic malignancies.Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemiaAnticancer treatment and thrombosis.Thrombotic disease in the myeloproliferative neoplasms.The mechanisms of cancer-associated thrombosis.Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography.Microparticles in tumor progression.LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4.Platelet haemostatic properties in β-thalassaemia: the effect of blood transfusion.ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.Effects of dexamethasone on pro-inflammatory cytokine expression, cell growth and maturation during granulocytic differentiation of acute promyelocytic leukemia cells.Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer.All-trans-retinoic acid and bleeding/thrombosis.Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties.Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism.Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.Hemostatic biomarkers in cancer progression.PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN).Heparin-like effect resistant to protamine in a child with haemorrhagic shock. Do we need heparinase?JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.Defining the thrombotic risk in patients with myeloproliferative neoplasms.Heparins inhibit the endothelial pro-thrombotic features induced by tumor cells.Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia veraPALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of BergamoPlatelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia veraProlonged bleeding time in patients with lupus anticoagulantDefibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cellsAspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathwayCancer and venous thromboembolism
P50
Q33399611-4870392D-CAF9-4744-AFE2-29BFF1789816Q35999309-B1CD336F-9C8B-4614-A25D-25F28CB8246EQ36012861-192126A1-4FBB-47B4-9546-EA3488A57B16Q36220059-325B6A6E-1BED-4891-813E-4C1B5D930A16Q36301071-8FE00CF4-617B-417F-9381-34644C09D5A7Q37000500-8EF02EE8-9AD3-41BE-8938-190D6FBB6952Q37246729-4F4955BF-4E79-48DA-88E0-9F916E33F2A1Q37596805-0C6A8C89-DCE0-424C-AB66-1572443FA2C9Q37625070-31C0520F-D652-4363-9135-48E588A59864Q37961377-8225D2E3-ADD0-436F-8166-A614E518B83FQ38066925-3C2EED5E-20EA-4B8F-B0AC-ED4AB80D7D23Q38436414-55C9348D-D06C-4016-82F7-52E719524C8AQ39379451-43A816A9-7430-4CA0-80B7-E3BF71AE8B8CQ39603636-6F914C15-307A-47C4-A84A-B66F9654E605Q39603869-45A0702E-7433-4EB3-8F6B-34F13C3D2491Q41202770-F07152AA-E6C4-4BAB-8200-B16D60927835Q41547084-07446492-A1CF-45A1-B262-AE2C6BBD015DQ42439502-3FDDA51E-0442-4DD6-A2AB-A0BFCBEF9B80Q42515223-CB81E806-3070-4483-948A-DFA11BAA197BQ43082685-9D0A2515-F25E-4CB7-B101-A455D6F659ADQ43982831-F5E0B189-BD53-4441-ADAB-39883191D948Q44573085-D7919728-5E1C-4DF5-84F0-9ED82FB67487Q45182874-7EC0AB0C-3E4E-450F-AC9B-D35A636B30FBQ46930461-C840B905-D7AF-490F-BB8D-ECC4D78E03E9Q47201370-EF8D1196-DA22-4711-830B-C490F84B649DQ50135977-80BADBBD-EFB2-440E-BA47-463596C083DAQ50644888-A8D64BF0-7272-4858-8CB1-36F0CF2DCEEAQ52716144-53D2FF49-904F-4FDC-AFB9-1C548FE4B729Q52870485-E33A9A19-AC85-4090-8935-757F47CB5D38Q53733712-6F28FE3E-7E34-430D-83C9-1C9E741FBC5BQ54574840-CD64713A-2B37-41D9-8EBE-994F03E86C3EQ54586582-250C3026-74D0-4B2A-B735-C738F60D5955Q54589969-623C436A-9834-4682-A652-D6011972CD37Q58411917-6461D113-0266-4F10-BF45-B333AFFE9A84Q60315437-940CCBCF-3030-485A-80B0-CCD6C3872BCAQ63367974-4E10FA2E-E585-4FCA-A4E8-5271B467BA3DQ67956023-B965AFBF-6DBB-46C2-A4BA-057D7441131BQ73720194-75D239E7-B089-40DB-93E8-EF471F2125E1Q74450016-9564D4AF-E468-47A9-9CF2-4FBE56361D84Q79197428-1B1632CA-641D-4548-B629-1C1A0917C6AE
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Marina Marchetti
@ast
Marina Marchetti
@en
Marina Marchetti
@es
Marina Marchetti
@nl
Marina Marchetti
@sl
type
label
Marina Marchetti
@ast
Marina Marchetti
@en
Marina Marchetti
@es
Marina Marchetti
@nl
Marina Marchetti
@sl
prefLabel
Marina Marchetti
@ast
Marina Marchetti
@en
Marina Marchetti
@es
Marina Marchetti
@nl
Marina Marchetti
@sl
P1006
P214
P1006
P106
P1153
16638331700
P21
P214
P31
P496
0000-0001-9036-960X